The IP was developed in
The 'tissues' created via the process are stronger and more durable, the company said, and can be used to replace skin, tendon, bone, cartilage, blood vessels and nerve conduits.
The company said that the advantage of the products to natural materials are their strength and rapid production time.
"The licensing of this IP is designed to integrate our specialist collagen capabilities with the diverse biomedical capacity and global research standing of UCL and will drive forward patient benefit in many new areas of regenerative medicine," said Chief Executive
No financial details if the deal were disclosed.
Most Popular Stories
- Florida Warns Beach-goers About Flesh-eating Bacteria
- Sutherland Responds to 'Unprofessional' Jibe
- Islamic State Fights for Control of Syrian Oil Wealth
- LivePro Is a Mobile Hot Spot, Projector in One
- How to Fit Green Energy Into Your Portfolio
- Adrienne Bailon Disses Ex-Lover Rob Kardashian
- Sanctions Will Hit Russia Hard if Not Lifted Quickly
- U.S. Economy Grows at Fastest Pace in 10 Years
- Jerry Brown Favors More Shelters for Immigrant Kids
- Business Leaders Set for CHCC Convention